|
1
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li C, Hashimi SM, Good DA, Cao S, Duan W,
Plummer PN, Mellick AS and Wei MQ: Apoptosis and microRNA
aberrations in cancer. Clin Exp Pharmacol Physiol. 39:739–746.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garofalo M, Romano G, Di Leva G, Nuovo G,
Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2012.
|
|
5
|
Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou
C and Zhou J: A miR-200b/200c/429-binding site polymorphism in the
3′ untranslated region of the AP-2α gene is associated with
cisplatin resistance. PLoS One. 6:e290432011. View Article : Google Scholar
|
|
6
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: microRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nikitina EG, Urazova LN and Stegny VN:
MicroRNAs and human cancer. Exp Oncol. 34:2–8. 2012.PubMed/NCBI
|
|
8
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Piepoli A, Tavano F, Copetti M, Mazza T,
Palumbo O, Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia
G, et al: Mirna expression profiles identify drivers in colorectal
and pancreatic cancers. PLoS One. 7:e336632012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ru P, Steele R, Hsueh EC and Ray RB:
Anti-miR-203 upregulates SOCS3 expression in breast cancer cells
and enhances cisplatin chemosensitivity. Genes Cancer. 2:720–727.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakano K and Vousden KH: PUMA, a novel
proapoptotic gene, is induced by p53. Mol Cell. 7:683–694. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McKenna DJ, McDade SS, Patel D and McCance
DJ: MicroRNA 203 expression in keratinocytes is dependent on
regulation of p53 levels by E6. J Virol. 84:10644–10652. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Funamizu N, Lacy CR, Parpart ST, Takai A,
Hiyoshi Y and Yanaga K: MicroRNA-301b promotes cell invasiveness
through targeting TP63 in pancreatic carcinoma cells. Int J Oncol.
44:725–734. 2014.PubMed/NCBI
|
|
14
|
Funamizu N, Lacy CR, Fujita K, Furukawa K,
Misawa sT, Yanaga K and Manome Y: Tetrahydrouridine inhibits cell
proliferation through cell cycle regulation regardless of cytidine
deaminase expression levels. PLoS One. 7:e374242012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Funamizu N, Kamata Y, Misawa T, Uwagawa T,
Lacy CR, Yanaga K and Manome Y: Hydroxyurea decreases gemcitabine
resistance in pancreatic carcinoma cells with highly expressed
ribonucleotide reductase. Pancreas. 41:107–113. 2012. View Article : Google Scholar
|
|
16
|
Funamizu N, Okamoto A, Kamata Y, Misawa T,
Uwagawa T, Gocho T, Yanaga K and Manome Y: Is the resistance of
gemcitabine for pancreatic cancer settled only by overexpression of
deoxycytidine kinase? Oncol Rep. 23:471–475. 2010.PubMed/NCBI
|
|
17
|
Funamizu N1, Hu C, Lacy C, Schetter A,
Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, et al:
Macrophage migration inhibitory factor induces epithelial to
mesenchymal transition, enhances tumor aggressiveness and predicts
clinical outcome in resected pancreatic ductal adenocarcinoma. Int
J Cancer. 132:785–794. 2013. View Article : Google Scholar
|
|
18
|
Li J, Zheng Y, Sun G and Xiong S:
Restoration of miR-7 expression suppresses the growth of Lewis lung
cancer cells by modulating epidermal growth factor receptor
signaling. Oncol Rep. 32:2511–2516. 2014.PubMed/NCBI
|
|
19
|
Liu Y, Zhou Y, Feng X, An P, Quan X, Wang
H, Ye S, Yu C, He Y and Luo H: MicroRNA-126 functions as a tumor
suppressor in colorectal cancer cells by targeting CXCR4 via the
AKT and ERK1/2 signaling pathways. Int J Oncol. 44:203–210.
2014.
|
|
20
|
Bu P and Yang P: MicroRNA-203 inhibits
malignant melanoma cell migration by targeting versican. Exp Ther
Med. 8:309–315. 2014.PubMed/NCBI
|
|
21
|
Tian L, Li M, Ge J, Guo Y, Sun Y, Liu M
and Xiao H: MiR-203 is downregulated in laryngeal squamous cell
carcinoma and can suppress proliferation and induce apoptosis of
tumours. Tumour Biol. 35:5953–5963. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feber A, Xi L, Luketich JD, Pennathur A,
Landreneau RJ, Wu M, Swanson SJ, Godfrey TE and Litle VR: MicroRNA
expression profiles of esophageal cancer. J Thorac Cardiovasc Surg.
135:255–260; discussion 260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wei W, Wanjun L, Hui S, Dongyue C, Xinjun
Y and Jisheng Z: miR-203 inhibits proliferation of HCC cells by
targeting survivin. Cell Biochem Funct. 31:82–85. 2013. View Article : Google Scholar
|
|
24
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z
and Dong JT: Epigenetic silencing of miR-203 upregulates SNAI2 and
contributes to the invasiveness of malignant breast cancer cells.
Genes Cancer. 2:782–791. 2011. View Article : Google Scholar
|
|
26
|
Gottardo F, Liu CG, Ferracin M, Calin GA,
Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, et
al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol.
25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Greither T, Grochola LF, Udelnow A,
Lautenschläger C, Würl P and Taubert H: Elevated expression of
microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated
with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar
|
|
28
|
Ikenaga N, Ohuchida K, Mizumoto K, Yu J,
Kayashima T, Sakai H, Fujita H, Nakata K and Tanaka M: MicroRNA-203
expression as a new prognostic marker of pancreatic adenocarcinoma.
Ann Surg Oncol. 17:3120–3128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang A, Kaghad M, Wang Y, Gillett E,
Fleming MD, Dötsch V, Andrews NC, Caput D and McKeon F: p63, a p53
homolog at 3q27–29, encodes multiple products with transactivating,
death-inducing, and dominant-negative activities. Mol Cell.
2:305–316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang A, Schweitzer R, Sun D, Kaghad M,
Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, et al:
p63 is essential for regenerative proliferation in limb,
craniofacial and epithelial development. Nature. 398:714–718. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yuan M, Luong P, Hudson C, Gudmundsdottir
K and Basu S: c-Abl phosphorylation of ΔNp63α is critical for cell
viability. Cell Death Dis. 1:e162010. View Article : Google Scholar
|
|
32
|
Rinne T, Brunner HG and van Bokhoven H:
p63-associated disorders. Cell Cycle. 6:262–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yi R, Poy MN, Stoffel M and Fuchs E: A
skin microRNA promotes differentiation by repressing ‘stemness’.
Nature. 452:225–229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yuan Y, Zeng ZY, Liu XH, Gong DJ, Tao J,
Cheng HZ and Huang SD: MicroRNA-203 inhibits cell proliferation by
repressing ΔNp63 expression in human esophageal squamous cell
carcinoma. BMC Cancer. 11:572011. View Article : Google Scholar
|
|
35
|
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto
T, Kato S and Miyazono K: Modulation of microRNA processing by p53.
Nature. 460:529–533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hemann MT, Zilfou JT, Zhao Z, Burgess DJ,
Hannon GJ and Lowe SW: Suppression of tumorigenesis by the p53
target PUMA. Proc Natl Acad Sci USA. 101:9333–9338. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Michalak EM, Villunger A, Adams JM and
Strasser A: In several cell types tumour suppressor p53 induces
apoptosis largely via Puma but Noxa can contribute. Cell Death
Differ. 15:1019–1029. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Viticchiè G, Lena AM, Latina A, Formosa A,
Gregersen LH, Lund AH, Bernardini S, Mauriello A, Miano R, Spagnoli
LG, et al: MiR-203 controls proliferation, migration and invasive
potential of prostate cancer cell lines. Cell Cycle. 10:1121–1131.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Miao L, Xiong X, Lin Y, Cheng Y, Lu J,
Zhang J and Cheng N: miR-203 inhibits tumor cell migration and
invasion via caveolin-1 in pancreatic cancer cells. Oncol Lett.
7:658–662. 2014.PubMed/NCBI
|
|
40
|
Li J, Chen Y, Zhao J, Kong F and Zhang Y:
miR-203 reverses chemoresistance in p53-mutated colon cancer cells
through downregulation of Akt2 expression. Cancer Lett. 304:52–59.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lena AM, Shalom-Feuerstein R, Rivetti di
Val Cervo P, Aberdam D, Knight RA, Melino G and Candi E: miR-203
represses ‘stemness’ by repressing DeltaNp63. Cell Death Differ.
15:1187–1195. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang C, Zheng X, Shen C and Shi Y:
MicroRNA-203 suppresses cell proliferation and migration by
targeting BIRC5 and LASP1 in human triple-negative breast cancer
cells. J Exp Clin Cancer Res. 31:582012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Takeshita N, Mori M, Kano M, Hoshino I,
Akutsu Y, Hanari N, Yoneyama Y, Ikeda N, Isozaki Y, Maruyama T, et
al: miR-203 inhibits the migration and invasion of esophageal
squamous cell carcinoma by regulating LASP1. Int J Oncol.
41:1653–1661. 2012.PubMed/NCBI
|
|
45
|
Okumura T, Shimada Y, Moriyama M, Takei Y,
Omura T, Sekine S, Nagata T, Shimizu K and Tsukada K: MicroRNA-203
inhibits the progression of esophageal squamous cell carcinoma with
restored epithelial tissue architecture in vivo. Int J Oncol.
44:1923–1932. 2014.PubMed/NCBI
|
|
46
|
He JH, Li YM, Li YG, Xie XY, Wang L, Chun
SY and Cheng WJ: hsa-miR-203 enhances the sensitivity of leukemia
cells to arsenic trioxide. Exp Ther Med. 5:1315–1321.
2013.PubMed/NCBI
|
